Novacyt S.A. Novacyt Partners with Applied Microarrays (6196A)
September 13 2018 - 2:00AM
UK Regulatory
TIDMNCYT
RNS Number : 6196A
Novacyt S.A.
13 September 2018
NOVACYT PARTNERS WITH APPLIED MICROARRAYS
IN ASSAY DESIGN
US partnership to facilitate the design and optimisation for
customised microarray assays
Paris, France and Camberley, UK - 13 September 2018 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, today announces its molecular testing
division, Primerdesign Ltd. (Primerdesign), has partnered with
Applied Microarrays, Inc. (AMI), a company that specialises in
providing customised microarrays and manufacturing point-of-care
(POC) and high throughput DNA and protein arrays, to offer
comprehensive single nucleotide polymorphism (SNP) assay
development.
Primerdesign will play an integral part in designing probes for
AMI and their customers. The microarray based molecular diagnostic
tests developed under this partnership will play a crucial role in
the early diagnosis, as well as improve patient management and
outcome. Primerdesign has thirteen years' experience in molecular
assay design and this partnership highlights the division's pivotal
role in assay development as it grows its relationships with
leading diagnostic companies.
Working together, Primerdesign and AMI can provide a full suite
of assay development services from probe designs, through to assay
optimisation, regulatory and ultimately high volume manufacturing
of SNP microarrays for use in POC as well as laboratory-based
settings.
Alastair Malcolm, President & CEO of AMI, commented:
"Novacyt is an expert in molecular diagnostic assay design and
development and I am pleased to enter this strategic partnership to
develop customised microarray based diagnostic tests. Through
working with Primerdesign, we have been impressed with their assay
development expertise and ability to deliver a high quality service
in a timely manner. I am confident that our partnership will help
us to deliver multiplexed probe based diagnostic and detection with
better diagnosis and improved patient outcomes."
Graham Mullis, Group CEO of Novacyt, added:
"I am delighted that we are entering into a partnership with
AMI. This partnership significantly expands our offering and
geographic reach as we continue to expand our molecular products
business.
"I am also pleased to see continued progress in our
business-to-business opportunities converting into commercial
partnerships. We are increasingly becoming the partner of choice
for molecular diagnostic companies and I look forward to updating
shareholders with further partnerships like this."
Financial terms of the agreement have not been disclosed.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint
Broker)
Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is a rapidly growing, international
diagnostics group with a growing portfolio of cancer and infectious
disease products and services. Through its proprietary technology
platform, NOVAPrep(R) , and molecular platform, genesig(R) ,
Novacyt is able to provide an extensive range of oncology and
infectious disease diagnostic products across an extensive
international distributor network. The Group has diversified sales
from diagnostic reagents used in oncology, microbiology,
haematology and serology markets, and its global customers and
partners include major corporates.
For more information please visit: www.novacyt.com
About Applied Microarrays
AMI is a company headquartered in Tempe, AZ, which designs,
optimises and manufactures DNA and protein biosensors, and other
microarrays on glass, plastic and semiconductors. AMI operates
under ISO 9001 and ISO 13485 certification. Since acquiring GE
Healthcare's microarray business in 2007, AMI has evolved to become
a full service provider for RUO and Dx devices.
For more information please visit: www.appliedmicroarrays.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSFLESEFASEIU
(END) Dow Jones Newswires
September 13, 2018 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024